Clinical Trial Detail

NCT ID NCT03972046
Title Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors David Lee
Indications

skin melanoma

melanoma

Therapies

Dabrafenib + Talimogene laherparepvec + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST